Katrine Bosley

Biography

Katrine Bosley has served as a member of our board of directors since 2013. Ms. Bosley is the President, Chief Executive Officer and member of the board of directors of Editas Medicine, Inc. since June 2014. Prior to joining Editas, she was the Entrepreneur-in-Residence at The Broad Institute from 2013 to 2014. From 2009 to 2012, she was President, Chief Executive Officer and member of the board of directors of Avila Therapeutics, Inc., which was acquired by Celgene Corporation in 2012. She served as President, Celgene Avilomics Research at Celgene in 2012. Prior to her time at Avila Therapeutics, she was Vice President, Strategic Operations at Adnexus, a Bristol-Myers Squibb R&D Company, and before that she was Vice President, Business Development at Adnexus Therapeutics, Inc. Ms. Bosley joined Adnexus Therapeutics from Biogen Idec, Inc. where she had roles in business development, commercial operations and portfolio strategy in the United States and Europe. Earlier, she was part of the healthcare team at the venture firm Highland Capital Partners, Inc. Ms. Bosley graduated from Cornell University with a B.A. in Biology. She currently serves as chairman of the board of Genocea Biosciences, Inc. She also serves on the board of directors of the Biotechnology Innovation Organization and is a review committee member of the Wellcome Trust. In the past, Ms. Bosley has also served as a member of the board of directors of Coco Therapeutics Limited and Scholar Rock, LLC. Katrine Bosley has served as a member of our board of directors since 2013. Ms. Bosley is the President, Chief Executive Officer and member of the board of directors of Editas Medicine, Inc. since June 2014. Prior to joining Editas, she was the Entrepreneur-in-Residence at The Broad Institute from 2013 to 2014. From 2009 to 2012, she was President, Chief Executive Officer and member of the board of directors of Avila Therapeutics, Inc., which was acquired by Celgene Corporation in 2012. She served as President, Celgene Avilomics Research at Celgene in 2012. Prior to her time at Avila Therapeutics, she was Vice President, Strategic Operations at Adnexus, a Bristol-Myers Squibb R&D Company, and before that she was Vice President, Business Development at Adnexus Therapeutics, Inc. Ms. Bosley joined Adnexus Therapeutics from Biogen Idec, Inc. where she had roles in business development, commercial operations and portfolio strategy in the United States and Europe. Earlier, she was part of the healthcare team at the venture firm Highland Capital Partners, Inc. Ms. Bosley graduated from Cornell University with a B.A. in Biology. She currently serves as chairman of the board of Genocea Biosciences, Inc. She also serves on the board of directors of the Biotechnology Innovation Organization and is a review committee member of the Wellcome Trust. In the past, Ms. Bosley has also served as a member of the board of directors of Coco Therapeutics Limited and Scholar Rock, LLC.

Research Interest

pharma